Pipeline Therapeutics Entered into a Global License and Development Agreement with Janssen for PIPE-307 to Treat Nervous System Disorders
Shots:
- Pipeline will receive $50M up front, ~$25M in equity investment from Johnson & Johnson, and ~ $25M in equity investments from Pipeline’s existing investors, ~$1B in milestones along with royalty if PIPE-307 proves successful
- Janssen gets an exclusive license globally to research, develop & commercialize PIPE-307 in all indications. Pipeline to get the right to advance PIPE-307, an oral, highly selective antagonist of the muscarinic M1 receptor for RRMS through P-II trial
- The collaboration uses Pipeline’s expertise in precision neuroregeneration & Janssen’s development experience across nervous system disorders to develop PIPE-307 for RRMS & other neurological disorders. 2 P-I trials for PIPE-307 in healthy volunteers have been completed
Ref: BusinessWire | Image: Pipeline Therapeutics
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
